Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)

The Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies, managed by the National Institutes of Health (NIH) through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to further research in regenerative medicine. This effort uses remaining funds from the 21st Century Cures Act, focusing on advancing regenerative medicine using adult stem cells. While this is a forecasted opportunity, the NIH is providing early notice to allow potential applicants to form meaningful collaborations and develop comprehensive project proposals. The initiative falls under the discretionary grant category and will be administered through cooperative agreements using the UH3 activity code, without allowing clinical trials. The grant is specifically structured to fund investigator-initiated studies that continue the momentum of prior RMIP efforts. Investigators previously funded under this project are especially encouraged to prepare for participation in this new funding opportunity. The notice explicitly states that applications are not currently being accepted, emphasizing the intent to give applicants ample preparation time. NIAMS anticipates publishing the official Notice of Funding Opportunity (NOFO) on August 1, 2025. Eligible applicants include a wide range of entities such as state governments, local county governments, federally and non-federally recognized tribal organizations, school districts, higher education institutions (both public and private), small businesses, and nonprofits with 501(c)(3) status. For-profit organizations outside the small business category and public housing authorities are also eligible. This broad eligibility reflects the inclusive scope of the RMIP's mission to engage a wide community in regenerative medicine research. The estimated timeline for the grant includes an application due date of October 21, 2025, with award announcements expected by June 22, 2026. Projects are anticipated to begin on July 21, 2026. As of now, specific details regarding total program funding, individual award ceilings or floors, and the number of awards have not been disclosed. Applicants seeking further information or planning to develop a proposal can contact Dr. Aron Marquitz at the National Institute of Arthritis and Musculoskeletal and Skin Diseases. He can be reached via email at [email protected] or by phone at 301-435-1240. The announcement encourages early preparation to ensure robust and innovative applications. The forecasted opportunity is listed under assistance listing 93.846, which covers research in arthritis, musculoskeletal, and skin diseases. The absence of a cost-sharing or matching requirement makes this opportunity accessible for institutions without substantial matching fund capabilities. While application materials are not yet available, applicants are advised to monitor the official NOFO release for specific submission requirements and evaluation criteria.